March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025 - The Centre hospitalier de l'Université de...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The Corporate LiveWire Innovation & Excellence Awards celebrate...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David Uffer, M.A, MBA joins NexPlasmaGen's Board of...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award. "GHP Magazine's Biotechnology Awards 2024” are...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for...
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie (MEIE), the National Research Council of Canada...